Evaluation of choloroquin, meloxicam and paracetamol in the chikungunya related chronic rheumatic musculoskeletal pains and disorders
Not Applicable
Completed
- Registration Number
- CTRI/2010/091/000208
- Lead Sponsor
- ARCF
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
Patients of either sex and  20 years of age
Diagnosis of clinically suspected Chikungunya (classical/ probable )
Chronic RMS pains of at least 4 weeks duration post febrile onset
Pains with a score of 4 on painVAS in past 24 hours
Patients not receiving regular anti- inflammatory drug or analgesic drugs
Willing to come for regular follow ? up visits
Signed Informed Consent and patient information sheet
Exclusion Criteria
Confirmed diagnosis for febrile illness other then Chikungunya
Patient with any other inflammatory form of arthritis
Hypersensitivity to any of the study medication drugs
Any condition that, in the opinion of the investigator, does not justify the patient?s inclusion for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PAIN VASTimepoint: 24 WEEKS- ONCE EVERY MONTH
- Secondary Outcome Measures
Name Time Method JOINT COUNT FOR PAIN AND TENDERNESS<br>JOINT COUNT FOR SWELLING<br>PHYSICIAN GLOBAL ASSESSMENT<br>PATIENT GLOBAL ASSESSMENT<br>HEALTH ASSESSSMENT QUESTIONNAIRE<br>PARACETAMOL CONSUMPTIONTimepoint: 24 WEEKS-ONCE EVERY MONTH